Details
Stereochemistry | ACHIRAL |
Molecular Formula | C32H32N4O3.ClH |
Molecular Weight | 557.082 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1CCC2(COC3=CC4=C(C=C23)N(CC4)C(=O)C5=CC=C(C=C5)C6=C(C)C=C(C=C6)C7=NOC(C)=N7)CC1
InChI
InChIKey=GKGKBZYMDILCOF-UHFFFAOYSA-N
InChI=1S/C32H32N4O3.ClH/c1-20-16-25(30-33-21(2)39-34-30)8-9-26(20)22-4-6-23(7-5-22)31(37)36-13-10-24-17-29-27(18-28(24)36)32(19-38-29)11-14-35(3)15-12-32;/h4-9,16-18H,10-15,19H2,1-3H3;1H
SB-224289 was originally developed by SmithKline, now known as GlaxoSmithKline. It was identified as an antagonist of the 5-hydroxytryptamine receptor 1B (5-HT1B) and subsequently investigated for potential antidepressant activity, although no human trials have been reported. Interestingly, SB-224289 was also found to exhibit antagonistic activity for the antifungal mechanism of Marine Depsipeptide Papuamide A in Candida albicans; although the specific mechanism of action remains unknown.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9652357
Curator's Comment: referenced study was conducted in guinea pig
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9225280
Curator's Comment: SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P28222 Gene ID: 3351.0 Gene Symbol: HTR1B Target Organism: Homo sapiens (Human) |
8.0 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9652357
The regulation of extracellular 5-HT1B receptors by SB-224289 was investigated in Guinea pigs which were dosed via intraperitoneal injection at a concentration of 4 mg/kg. SB-224289 had no effect on 5-HT levels in frontal cortex or striatum. In the dentate gyrus SB-224289 significantly increased extracellular 5-HT, reaching maxima of 151+/-19% of basal levels.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9225280
Human 5-HT1B and 5-HT1D receptors were stably transfected into the Chinese Hamster Ovary (ACC098) cell line. Competition studies were performed to determine the affinity of SB-224289 at both h5-HT1B and h5-HT1D receptor subtypes. SB-224289 was also equal to or greater than 75 fold selective for the h5-HT1B receptor over the other human 5-HT receptor subtypes exhibiting a pKi of 8 for human 5HT1B.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
RTX59ZSB74
Created by
admin on Sat Dec 16 08:09:17 GMT 2023 , Edited by admin on Sat Dec 16 08:09:17 GMT 2023
|
PRIMARY | |||
|
DTXSID9042627
Created by
admin on Sat Dec 16 08:09:17 GMT 2023 , Edited by admin on Sat Dec 16 08:09:17 GMT 2023
|
PRIMARY | |||
|
180084-26-8
Created by
admin on Sat Dec 16 08:09:17 GMT 2023 , Edited by admin on Sat Dec 16 08:09:17 GMT 2023
|
PRIMARY | |||
|
11226716
Created by
admin on Sat Dec 16 08:09:17 GMT 2023 , Edited by admin on Sat Dec 16 08:09:17 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD